Neurovance Overview
- Year Founded
-
2011
- Status
-
Acquired/Merged
- Employees
-
6
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$250M
Neurovance General Information
Description
Developer of a triple re-uptake inhibitor designed to address lack of focus, inattention and disorganization in ADHD patients. The company's triple re-uptake inhibitor Centanafadine (CTN) modulates the activity of norepinephrine, dopamine and serotonin in a specific ratio to affect a specific result, helping patients with ADHD, attention-deficit hyperactivity disorder.
Contact Information
Website
www.neurovance.comCorporate Office
- 43 Thorndike Street
- Suite S1-3
- Cambridge, MA 02141
- United States
Corporate Office
- 43 Thorndike Street
- Suite S1-3
- Cambridge, MA 02141
- United States
Neurovance Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Merger/Acquisition | 01-Mar-2017 | $250M | Completed | Clinical Trials - Phase 3 | ||
| 4. Early Stage VC | 29-Feb-2016 | Completed | Clinical Trials - Phase 3 | |||
| 3. Early Stage VC (Series A1) | 29-Jun-2015 | Completed | Clinical Trials - Phase 1 | |||
| 2. Early Stage VC (Series A1) | 14-Mar-2014 | $10.5M | $11M | Completed | Startup | |
| 1. Early Stage VC (Series A) | 30-May-2012 | $478K | $478K | Completed | Startup |
Neurovance Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A1 | ||||||||
| Series A |
Neurovance Comparisons
Industry
Financing
Details
Neurovance Competitors (10)
One of Neurovance’s 10 competitors is Voyager Therapeutics, a Formerly VC-backed company based in Lexington, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Voyager Therapeutics | Formerly VC-backed | Lexington, MA | ||||
| Curemark | Venture Capital-Backed | New York, NY | ||||
| T3D Therapeutics | Venture Capital-Backed | Durham, NC | ||||
| Alzheon | Venture Capital-Backed | Framingham, MA | ||||
| Vertex Pharmaceuticals | Formerly VC-backed | Boston, MA |
Neurovance Patents
Neurovance Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2017502948-A | Novel composition | Inactive | 09-Dec-2013 | ||
| AU-2014374259-A1 | Novel compositions | Inactive | 09-Dec-2013 | ||
| CA-2936108-A1 | Novel compositions | Inactive | 09-Dec-2013 | ||
| EP-3080080-A1 | Novel compositions | Inactive | 09-Dec-2013 | ||
| EP-3080080-A4 | Novel compositions | Inactive | 09-Dec-2013 | A61K31/403 |
Neurovance Signals
Neurovance Former Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Clarevia Ventures | Venture Capital | Minority | ||
| GBS Venture Partners | Venture Capital | Minority | ||
| Novartis Venture Fund | Corporate Venture Capital | Minority | ||
| State of Wisconsin Investment Board | Government | Minority | ||
| abrdn Healthcare Investors | Hedge Fund | Minority |
Neurovance FAQs
-
When was Neurovance founded?
Neurovance was founded in 2011.
-
Where is Neurovance headquartered?
Neurovance is headquartered in Cambridge, MA.
-
What is the size of Neurovance?
Neurovance has 6 total employees.
-
What industry is Neurovance in?
Neurovance’s primary industry is Drug Discovery.
-
Is Neurovance a private or public company?
Neurovance is a Private company.
-
What is the current valuation of Neurovance?
The current valuation of Neurovance is .
-
What is Neurovance’s current revenue?
The current revenue for Neurovance is .
-
How much funding has Neurovance raised over time?
Neurovance has raised $45.5M.
-
Who are Neurovance’s investors?
Clarevia Ventures, GBS Venture Partners, Novartis Venture Fund, State of Wisconsin Investment Board, and abrdn Healthcare Investors have invested in Neurovance.
-
Who are Neurovance’s competitors?
Voyager Therapeutics, Curemark, T3D Therapeutics, Alzheon, and Vertex Pharmaceuticals are some of the 10 competitors of Neurovance.
-
When was Neurovance acquired?
Neurovance was acquired on 01-Mar-2017.
-
Who acquired Neurovance?
Neurovance was acquired by Otsuka Holdings.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process